title: [11C]Acetate rest-stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats.
abstract: This study describes an [(11)C]acetate rest-stress method to obtain an indirect estimate of myocardial blood flow (MBF) and myocardial oxygen consumption (MVO(2)) in rats. Doxorubicin cardiotoxicity was used to test the usefulness of this approach for the assessment of congestive heart failure.
  
  
  METHODS
  [(11)C]Acetate rest-stress studies have been used in clinical research to assess the capacity of the coronary arteries to respond to stress. In this article, we used this approach to assess the cardiotoxicity of doxorubicin in a rat model. The method was first validated in a group of healthy rats and then used to follow the effect of doxorubicin chemotherapy on cardiac function. The effect of doxorubicin on myocardial perfusion and oxygen consumption reserve was measured at rest and under dobutamine stimulation.
  
  
  RESULTS
  Validation of the protocol showed a good correlation between the MBF and MVO(2) (r(2)=.68). The doxorubicin-treated group showed a significant (P=.04) decrease in cardiovascular perfusion reserve at 1.3±0.2 compared with the control animals at 1.6±0.2. Similar results were obtained for the MVO(2) reserve (treated 1.8±0.4 vs. controls 2.3±0.3; P=.02).
  
  
  CONCLUSIONS
  We describe an [(11)C]acetate PET rest-stress protocol for the assessment of congestive heart failure in rats and its application to the follow-up of cardiotoxicity under doxorubicin chemotherapy. This is a rapid and reliable approach to the measurement of cardiac perfusion and oxygen consumption reserve that could be applied to the development of new strategies to reduce the cardiotoxicity of anthracycline.
authors.affiliation: Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke and Sherbrooke Molecular Imaging Center, Étienne-LeBel Clinical Research Center, CHUS, Sherbrooke, QC, Canada. etienne.croteau@usherbrooke.ca
authors.forename: Etienne
authors.initials: E
authors.lastname: Croteau
authors.forename: Suzanne
authors.initials: S
authors.lastname: Gascon
authors.forename: M'hamed
authors.initials: M
authors.lastname: Bentourkia
authors.forename: Réjean
authors.initials: R
authors.lastname: Langlois
authors.forename: Jacques A
authors.initials: JA
authors.lastname: Rousseau
authors.forename: Roger
authors.initials: R
authors.lastname: Lecomte
authors.forename: François
authors.initials: F
authors.lastname: Bénard
mesh_terms: D000085:Acetates; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D002250:Carbon Radioisotopes; D016022:Case-Control Studies; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D004317:Doxorubicin / Q000494:pharmacology; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000503:physiopathology; D055414:Myocardial Perfusion Imaging / Q000379:methods*; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology*; D049268:Positron-Emission Tomography / Q000379:methods*; D051381:Rats
chemical_list: D000085:Acetates; D000903:Antibiotics, Antineoplastic; D002250:Carbon Radioisotopes; D004317:Doxorubicin
references.citation: Eur J Nucl Med. 2000 Mar;27(3):319-26
references.pmid: 10774885
references.citation: NMR Biomed. 2002 May;15(3):222-34
references.pmid: 11968138
references.citation: Eur Heart J. 2004 Apr;25(7):565-70
references.pmid: 15120053
references.citation: Hypertension. 2004 Oct;44(4):465-70
references.pmid: 15326083
references.citation: J Nucl Med. 1998 Feb;39(2):272-80
references.pmid: 9476935
references.citation: J Am Coll Cardiol. 1988 Oct;12(4):1054-63
references.pmid: 3262128
references.citation: Hypertension. 2007 Jul;50(1):242-7
references.pmid: 17502492
references.citation: Eur J Nucl Med. 2001 May;28(5):651-68
references.pmid: 11383873
references.citation: Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1453-9
references.pmid: 19387639
references.citation: J Nucl Med. 1991 Oct;32(10):1950-7
references.pmid: 1919738
references.citation: J Nucl Med. 2009 Mar;50(3):390-6
references.pmid: 19223407
references.citation: J Nucl Med. 2006 Mar;47(3):477-85
references.pmid: 16513617
references.citation: J Nucl Med. 2006 Mar;47(3):378-83
references.pmid: 16513605
references.citation: Arzneimittelforschung. 1978;28(5):798-801
references.pmid: 581958
references.citation: J Nucl Med. 2004 Nov;45(11):1924-30
references.pmid: 15534064
references.citation: Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):7-23
references.pmid: 1094804
references.citation: Pharmacol Toxicol. 2003 Sep;93(3):105-15
references.pmid: 12969434
references.citation: J Nucl Med. 1989 Feb;30(2):187-93
references.pmid: 2786932
references.citation: Eur J Heart Fail. 2005 Mar 2;7(2):225-30
references.pmid: 15701471
references.citation: J Vasc Res. 2003 Jul-Aug;40(4):416-22
references.pmid: 12913334
references.citation: J Nucl Med. 1991 Feb;32(2):245-51
references.pmid: 1992027
references.citation: Coron Artery Dis. 2007 Feb;18(1):15-22
references.pmid: 17172925
references.citation: Circulation. 1974 Dec;50(6):1179-89
references.pmid: 4430113
references.citation: Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1466-83
references.pmid: 19286953
references.citation: Nucl Med Commun. 2011 Apr;32(4):260-4
references.pmid: 21285908
references.citation: J Nucl Med. 1989 Sep;30(9):1489-99
references.pmid: 2788722
references.citation: Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1592-8
references.pmid: 15290120
references.citation: Am J Vet Res. 1998 Feb;59(2):182-5
references.pmid: 9492933
references.citation: Eur J Nucl Med. 1999 Nov;26(11):1465-74
references.pmid: 10552089
references.citation: Toxicol Appl Pharmacol. 2004 Oct 15;200(2):159-68
references.pmid: 15476868
references.citation: Am J Cardiol. 1997 Aug 4;80(3A):3A-10A
references.pmid: 9293950
references.citation: J Nucl Med. 2008 May;49(5):738-45
references.pmid: 18413384
references.citation: Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1539-50
references.pmid: 20437239